Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Tara C MarcinkDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. tm2996@cumc.columbia.edu.ORCID 0000-0003-4295-1229
Gillian ZipurskyDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Elizabeth B SobolikDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID 0000-0003-3539-0718
Kate GolubDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Emily HermanDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Kyle StearnsDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Alexander L GreningerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-7443-0527
Matteo PorottoDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID 0000-0003-3866-9220
Anne MosconaDepartment of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. am939@cumc.columbia.edu.ORCID 0000-0002-1796-8320
Funding
Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPPU19AI181984 · NIAID · WASHINGTON UNIVERSITY · PI MOSCONA, ANNE · 2024 to 2024
$44.1M
Engineering protease-resistant alpha-beta peptides for broad-spectrum antiviralsR01AI114736 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 2015 to 2019
$3.7M
Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2R01AI160961 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOSCONA, ANNE · 2021 to 2025
$3.6M
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2R01AI160953 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2021 to 2025
$3.6M
Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agentsR01AI121349 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2016 to 2020
$3.2M
Broad spectrum inhibitors of paramyxovirus envelope proteinsR01AI175362 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Anne Moscona · 2023 to 2026
$3.2M
Human parainfluenza virus fusion complexglycoproteins imaged in actionF32AI152275 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MARCINK, TARA · 2021 to 2023
$177k
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) AI114736Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) AI121349Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) AI152275Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) AI160953Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) AI160961NIAID NIH HHS F32 AI152275NIAID NIH HHS R01 AI114736NIAID NIH HHS R01 AI121349NIAID NIH HHS R01 AI160953NIAID NIH HHS R01 AI160961NIAID NIH HHS R01 AI175362NIAID NIH HHS U19 AI181984
6 · The paper itself
Abstract
Paramyxoviruses including measles, Nipah, and parainfluenza viruses are public health threats with pandemic potential. Human parainfluenza virus type 3 (HPIV3) is a leading cause of illness in pediatric, older, and immunocompromised populations. There are no approved vaccines or therapeutics for HPIV3. Neutralizing monoclonal antibodies (mAbs) that target viral fusion are a potential strategy for mitigating paramyxovirus infection, however their utility may be curtailed by viral evolution that leads to resistance. Paramyxoviruses enter cells by fusing with the cell membrane in a process mediated by a complex consisting of a receptor binding protein (HN) and a fusion protein (F). Existing atomic resolution structures fail to reveal physiologically relevant interactions during viral entry. We present cryo-ET structures of pre-fusion HN-F complexes in situ on surfaces of virions that evolved resistance to an anti-HPIV3 F neutralizing mAb. Single mutations in F abolish mAb binding and neutralization. In these complexes, the HN protein that normally restrains F triggering has shifted to uncap the F apex. These complexes are more readily triggered to fuse. These structures shed light on the adaptability of the pre-fusion HN-F complex and mechanisms of paramyxoviral resistance to mAbs, and help define potential barriers to resistance for the design of mAbs.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
How a paramyxovirus fusion/entry complex adapts to escape a neutralizing antibody. · full record | OpenQuestion